Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 09/27 04:24:20 pm
18810 ILa   -1.72%
09/26 TEVA PHARMACEUT : Shareholders sue Teva over Rimsa acquisition
09/23 TEVA PHARMACEUT : TEVA) Unveils Successful AIM-TD Clinical Trial Res..
09/22DJTEVA PHARMACEUT : Huntington Disease Drug Meets Primary Endpoint
News SummaryMost relevantAll newsSector news 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
07/01/2013 | 01:27pm CEST
   By Melodie Warner 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
09/26 TEVA PHARMACEUTICAL INDUSTRIES : Shareholders sue Teva over Rimsa acquisition
09/23 TEVA PHARMACEUTICAL INDUSTRIES LTD. : TEVA) Unveils Successful AIM-TD Clinical ..
09/22DJTEVA PHARMACEUTICAL INDUSTRIES : Huntington Disease Drug Meets Primary Endpoint
09/22 TEVA PHARMACEUTICAL INDUSTRIES : Announces Positive Top-Line Data from Second Ph..
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/21 MYLAN : shares languish at low valuation as EpiPen hearing nears
09/20 REGENERON PHARMACEUTICALS : Teva buys rights to Regeneron chronic pain drug for ..
09/20 TEVA PHARMACEUTICAL INDUSTRIES : and Regeneron Announce Global Collaboration to ..
09/20 TEVA PHARMACEUTICAL INDUSTRIES : Regeneron and Teva Announce Global Collaboratio..
09/19 TEVA PHARMACEUTICAL INDUSTRIES : Announces Results from Exploratory 52-Week Phas..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:03a A Sudden Abundance Of Warning Signs
09/25 TEVA : Buy For Today's Value And Tomorrow's Growth
09/23 SNIPPET ROUNDUP : Firsts For Chinese CAR Companies, Setbacks For J&J And Mast
09/22 In Teva, Regeneron Finds Its Sanofi For Pain
09/22 Teva's SD-809 successful in late-stage study in tardive dyskinesia; regulator..
Financials ($)
Sales 2016 22 447 M
EBIT 2016 7 361 M
Net income 2016 3 321 M
Debt 2016 25 666 M
Yield 2016 2,28%
P/E ratio 2016 11,70
P/E ratio 2017 9,66
EV / Sales 2016 3,44x
EV / Sales 2017 2,78x
Capitalization 51 659 M
More Financials
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 68,0 $
Spread / Average Target 33%
Consensus details
EPS Revisions
More Estimates Revisions
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results